Perineural 2-adrenoceptor activation relieves hypersensitivity induced by peripheral nerve injury or sciatic inXammatory neuritis. This eVect is associated with a reduction in pro-inXammatory cytokines, as well as a reduction in local leukocyte number and their capacity to produce pro-inXammatory cytokines. Curiously, clonidine's antinociceptive eVect appears with a 2-3-day delay after injection. Previous observations have shown that -adrenoceptor activation induces apoptosis in leukocytes, which would reduce leukocyte number. Additionally, macrophage scavenging of apoptotic cells results in a shift to an anti-inXammatory phenotype, with expression of transforming growth factor (TGF)-1. We therefore examined the eVects of perineural clonidine 24 h and 3 days after its injection on apoptosis, TGF-1 expression and lymphocyte and macrophage phenotype in acute sciatic inXammatory neuritis. Perineural clonidine reduced ipsilateral neuritis-induced hypersensitivity in a delayed manner (3 days after treatment), along with a reduction at this time in lymphocyte number and an increase in caspase-3 and TGF-1 expressing cells and macrophages co-expressing TGF-1 in the sciatic nerve. One day after injection clonidine treatment was associated with a reduction in lymphocytes and pro-inXammatory Th-1 cells as well as increased numbers of caspase-3 and TGF-1 expressing cells and macrophages co-expressing TGF-1 in sciatic nerve. Clonidine's eVects were prevented by co-administration of an 2-adrenoceptor antagonist. These data suggest that 2-adrenoceptor activation in sciatic inXammatory neuritis increases local apoptosis and anti-inXammatory products early after treatment. This early eVect likely underlies the delayed anti-inXammatory and anti-hypersensitivity eVects of perineural clonidine in this setting.
Introduction
Peripheral nerve injury induces chronic pain in part due to immune activation orchestrated by stimulation and migration of leukocytes and by their expression of proinXammatory products. Immune activation near healthy peripheral nerves is suYcient to produce pain states (Watkins et al., 1995) and peripheral immune modulation reduces hypersensitivity to somatic stimuli in several neuropathic pain models (Twining et al., 2004; Romero-Sandoval and Eisenach, 2006) . Sympathetic nervous system activity or exogenously applied adrenoceptor (AR) agonists can modulate activity and responses of lymphocytes and macrophages (Moynihan et al., 2004) , due to actions on multiple AR subtypes, including 2-ARs (Titnchi and Clark, 1984; Spengler et al., 1990; Josefsson et al., 1996) . Sympathetic and -AR activation have been suggested to contribute to peripheral nerve injury-induced pain (Sato and Perl, 1991; Koltzenburg and McMahon, 1991; McLachlan et al., 1993) . However, we have also shown that perineural 2-AR activation relieves neuropathic pain by modulating immune responses
